🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

Recruitingn/aAges 6 Months - 98 YearsAllNational Institute of Diabetes and Digestive and …
NCT05419037 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Lipodystrophy is a health problem in which the body does not have enough fat tissue. People with lipodystrophy may not make enough of the hormone leptin. Leptin regulates hunger. Low leptin levels trigger hunger. People with lipodystrophy can have many health problems. They may take a drug (metreleptin) that mimics leptin. Little is known about how taking metreleptin may affect a pregnancy. Metreleptin may be helpful or harmful to pregnant women. It may also affect the health of the child who is born. Objective: This natural history study will collect data about the effects of taking metreleptin while pregnant. Eligibility: Women aged 18 years or older with lipodystrophy who have been pregnant. Women who did and who did not take metreleptin during their pregnancies are needed. Children of women with lipodystrophy who took this drug during pregnancy are also needed. Desi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Women with lipodystrophy who had pregnancies with or without use of metreleptin: * Female, aged \>= 18 years * Clinical diagnosis of non-HIV associated generalized or partial lipodystrophy * History of one or more pregnancies * Offspring of women with lipodystrophy who had pregnancies while taking metreleptin: * Males or females aged \>=1 month * Mothers took metreleptin during their pregnancy * Availability of a biobanked blood specimen or willingness to provide a blood specimen Note that subjects treated with metreleptin during pregnancy may participate in this study regardless of the participation of their offspring. EXCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must not meet any of the following criteria: * Inability of subject or guardian to understand or the unwillingness to sign a written informed consent document (except as noted below with \*) * Pregnancy. * Subjects who otherwise meet inclusion/exclusion criteria but who are not reachable to obtain informed consent may be included under a waiver of consent.
💊

What it tests

  • Not listed
📍

Where

1 site
National Institutes of Health Clinical Center
Bethesda, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy